Now available GAVRETO™

GAVRETO™ is a kinase inhibitor indicated for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion- positive nonsmall cell lung cancer (NSCLC) as detected by an FDA approved test.

Please see the full prescribing information.